Popular Articles

Israeli Startup CLT Partners With Dutch Erasmus Medical Centre To Develop A Cure For Atrial Fibrillation
Today, the Israeli medtech startup company CLT Ltd. announced the establishment of Closed Loop Therapies (CLT) BV - a joint venture between Erasmus University Medical Centre (Rotterdam, the Netherlands), a highly prominent medical institute in Europe, and CLT Israel. The joint venture aims to develop and commercialise a novel therapeutic system, consisting of an arrhythmia-detecting drug pump combined with a unique drug, for automatic and immediate treatment of emerging atrial fibrillation (AF). Market size is estimated at 2.5-3 billion Euro, annually.

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect On Pandemic H1N1 Influenza Virus After Oral Administration
ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBS), reports preliminary evidence that its selective Neurokinin 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.
News of the day
Medical Defence Union Encourages Doctors To Say Sorry If Things Go Wrong, UK
The Medical Defence Union (MDU) the UK"s largest medical defence organisation has reassured doctors that they are not admitting liability if they apologise when something has gone wrong with their treatment of a patient.
Health Insurance

Appeals Court Panel Says Pharmacists Must Distribute Emergency Contraception Under Washington State Regulation

A three-judge panel of the U.S. Circuit Court of Appeals for the 9th Circuit on Wednesday unanimously ruled to lift an injunction blocking Washington state officials from penalizing pharmacists who refused to dispense the emergency contraception pill Plan B, the Los Angeles Times reports (Williams, Los Angeles Times, 7/9). The panel said the district court judge who issued the injunction refused to consider women"s need for EC (Egelko, San Francisco Chronicle, 7/9). The panel"s ruling is part of a larger case before the district court involving the constitutionality of a 2007 state regulation requiring pharmacies to stock and dispense EC. Joyce Roper, an assistant attorney general for Washington state, said the appeals court ruling means that the 2007 regulation will take immediate effect.The plaintiffs in the case, Stromans -- a supermarket pharmacy owner -- and two pharmacists employed elsewhere, argued that the state regulation requiring pharmacists to stock and dispense EC violated their First Amendment right to freedom of religion (Los Angeles Times, 7/9). The regulation said that pharmacies must stock and fill legally prescribed prescriptions but allowed individual pharmacists to object on moral or religious grounds if another pharmacist was available, in person or by telephone, to fill the order (San Francisco Chronicle, 7/9). The plaintiffs argued that the regulation would force them to choose between following their religious beliefs and keeping their jobs. They contended that EC prevents implantation of a fertilized egg, which they equated with abortion. The U.S. District Court in Seattle awarded the plaintiffs the temporary injunction in November 2007, pending trial on the constitutionality of the regulation (Los Angeles Times, 7/9). Plan B contains a high dose of a drug found in most birth control pills that generally prevents ovulation or the fertilization of an egg. Recent research suggests that it does not prevent a fertilized egg from implanting in the uterus (Woodward, AP/Seattle Post-Intelligencer, 7/8). FDA in April lowered the age limit for nonprescription purchase of Plan B from 18 to 17 (San Francisco Chronicle, 7/9). Appeals Panel Returns Case to District CourtThe appeals court panel ruled that the freedom to exercise one"s religion "does not relieve an individual of the obligation to comply with a valid and neutral law of general applicability." The panel added, "Any refusal to dispense -- regardless of whether it is motivated by religion, morals, conscience, ethics, discriminatory prejudices or personal distaste for a patient -- violates the rules" (Los Angeles Times, 7/9). The panel ordered the district judge to reconsider the 2007 regulation under Supreme Court standards that allow states to pass neutral laws that may affect religious practices. According to the panel, the regulation does not aim to interfere with religious practices or beliefs and is intended to promote patients" health. In addition, the panel said the district court judge did not consider how the injunction would affect "sexually active women of childbearing age who will be denied reasonable access to Plan B" (San Francisco Chronicle, 7/9). According to the Times, the panel"s ruling could foretell future judgments in the case, including that a patient"s right to timely medication surpasses a pharmacist"s personal beliefs (Los Angeles Times, 7/9). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):